Ursolic Acid Conjugates: A New Frontier in Anticancer Drug Development

New Ursolic Acid (UA) conjugates were synthesized using optimized synthetic protocols through the molecular hybridization approach at C‐3 and C‐28. This resulted in the targeted molecules being produced in good yields. Some of the synthesized conjugates showed significantly relevant bioactivity against mammalian cells and in animal models of cancers. Selected UA conjugates were tested against bladder and breast cancer cell lines. The conjugates showed moderate to significantly enhanced antiproliferative activities against Triple Negative Breast Cancer (TNBC; MDA‐MB 231), which is an aggressive tumor making up about 10–15 % of all breast cancers and bladder (T24 and 5637) cancer cell lines. These properties were superior to the parent UA. Among all the synthesized compounds, 18 c and 18 d have exhibited promising antiproliferative and cytotoxic properties against all tested cancer cell lines. However, 18 d has proved to be exceptionally selective for cancer cell lines, showing more cytotoxicity towards them than normal epithelial cells (MCF‐12A). Compound 18 d has demonstrated cytotoxicity against tumor cells, including those intrinsically resistant to chemotherapy drugs such as 2‐difluoro‐deoxy cytidine (Gemcitabine). The activity of the UA conjugates on tumor cells was mediated by multiple cytotoxic mechanisms, including drug‐induced cytotoxic autophagy and programmed cell death, indicating a novel possibility of combination therapy. New ursolic acid (UA) conjugates were synthesized through molecular hybridization, targeting C‐3 and C‐28. These conjugates demonstrated improved antiproliferative activity against triple‐negative breast cancer (TNBC) and bladder cancer cell lines. Notably, compounds 18 c and 18 d exhibited significant cytotoxic properties, with 18 d showing exceptional selectivity for cancer cells over normal epithelial cells. Moreover, 18d demonstrated better pharmacokinetic properties.